First Solar revealed that the United States Patent and Trademark Office (USPTO) has denied three separate inter partes review ...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the ...
Renewal Fuels, Inc. (OTC: RNWF) (“RNWF” “American Fusion” or the “Company”), together with Kepler Fusion Technologies Inc., ...
On November 28, 2025, the United States Patent and Trademark Office (USPTO) issued revised examination guidance on inventorship for AI‑assisted inventions. The guidance rescinds the USPTO’s prior ...
Jan 20 (Reuters) - First Solar said on Tuesday the United States Patent and Trademark Office director denied three separate ...
On July 31, 2025, the acting Director of the United States Patent and Trademark Office (USPTO) published a memorandum making a significant change in Patent Trial and Appeal Board (PTAB) inter partes ...
This week on IPWatchdog Unleashed my conversation is with Kevin McNish, who is a registered patent attorney who represents clients in inter partes reviews (IPR), post-grant reviews (PGR), ex parte ...
USPTO Director Squires’s 2025 policies encourage more use of evidence-based SMEDs to challenge patent rejections, especially ...
According to Canadian Solar, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has ruled in its favor, stating that “all claims asserted by Maxeon ...
The United States Patent and Trademark Office announced plans to lay off about 1% of its workforce of over 14,000 employees as the agency continues to operate amid a government shutdown, according to ...
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...
Shares of JinkoSolar fell after the United States Patent and Trademark office declined to invalidate competitor First Solar's patents. The shares fell 12.8% to $25.78 in Tuesday afternoon trading. The ...